UroGen Pharma (URGN) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 03, 2021
Document Information [Line Items]
Entity Central Index Key	0001668243
Entity Registrant Name	UroGen Pharma Ltd.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park Drive
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Trading Symbol	URGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,420,325

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 55,337	$ 52,864
Marketable securities	50,872	49,154
Restricted cash	1,226	1,226
Accounts receivable	7,784	7,047
Inventories	3,808	1,964
Prepaid expense and other current assets	6,113	3,364
Total current assets	125,140	115,619
Non-current assets:
Property and equipment, net	1,978	2,046
Restricted deposit	223	223
Right of use asset	1,418	2,158
Marketable securities	4,071	1,893
Other non-current assets	1,773	66
Total Assets	134,603	122,005
Current liabilities:
Accounts payable and accrued expense	11,062	10,023
Employee related accrued expense	6,476	9,554
Other current liabilities	2,268	1,859
Total current liabilities:	19,806	21,436
Non-current liabilities:
Prepaid forward obligation	79,927	0
Long-term lease liability	616	1,497
Uncertain tax positions liability	2,717	2,717
Total Liabilities	103,066	25,650
Commitments and contingencies (Note 14)
Shareholders' equity:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at September 30, 2021 and December 31, 2020; 22,404,845 and 22,167,791 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	61	60
Additional paid-in capital	470,341	452,525
Accumulated deficit	(438,869)	(356,501)
Accumulated other comprehensive income	4	271
Total Shareholders' Equity	31,537	96,355
Total Liabilities and Shareholders' Equity	$ 134,603	$ 122,005

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - ₪ / shares	Sep. 30, 2021	Dec. 31, 2020
Ordinary shares, par value (in ILS per share)	₪ 0.01	₪ 0.01
Ordinary shares, authorized (in shares)	100,000,000	100,000,000
Ordinary shares, issued (in shares)	22,404,845	22,167,791
Ordinary shares, outstanding (in shares)	22,404,845	22,167,791

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 11,351	$ 3,461	$ 31,868	$ 3,833
Cost of revenue	1,244	309	3,568	357
Gross profit	10,107	3,152	28,300	3,476
Operating expense:
Research and development expense	11,923	10,211	34,560	34,905
Selling, general and administrative expense	21,624	22,065	66,117	68,056
Operating loss	(23,440)	(29,124)	(72,377)	(99,485)
Financing on prepaid forward obligation	(6,828)	0	(9,948)	0
Interest and other income, net	57	308	269	1,527
Loss before income taxes	(30,211)	(28,816)	(82,056)	(97,958)
Income tax expense	0	0	312	0
Net Loss	(30,211)	(28,816)	(82,368)	(97,958)
Statements of Comprehensive Loss
Net loss	(30,211)	(28,816)	(82,368)	(97,958)
Other comprehensive income
Unrealized (loss) gain on marketable securities	(41)	(268)	(267)	216
Comprehensive Loss	$ (30,252)	$ (29,084)	$ (82,635)	$ (97,742)
Net loss per ordinary share basic and diluted (in dollars per share)	$ (1.35)	$ (1.31)	$ (3.69)	$ (4.52)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	22,380,598	22,058,343	22,318,589	21,657,712

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2019	21,026,184
Balance at Dec. 31, 2019	$ 57	$ 407,986	$ (228,017)	$ 276	$ 180,302
Exercise of options into ordinary shares (in shares)	345,248
Exercise of options into ordinary shares	$ 1	690			691
Share-based compensation		21,499			21,499
Other comprehensive income (loss)				216	216
Net loss			(97,958)		(97,958)
Issuance of ordinary shares in public offering, net of issuance expense (in shares)	700,000
Issuance of ordinary shares in public offering, net of issuance expense	$ 2	15,775			15,777
Balance (in shares) at Sep. 30, 2020	22,071,432
Balance at Sep. 30, 2020	$ 60	445,950	(325,975)	492	120,527
Balance (in shares) at Jun. 30, 2020	22,001,296
Balance at Jun. 30, 2020	$ 60	438,999	(297,159)	760	142,660
Exercise of options into ordinary shares (in shares)	70,136
Exercise of options into ordinary shares	$ 0	188			188
Share-based compensation		6,763			6,763
Other comprehensive income (loss)				(268)	(268)
Net loss			(28,816)		(28,816)
Balance (in shares) at Sep. 30, 2020	22,071,432
Balance at Sep. 30, 2020	$ 60	445,950	(325,975)	492	120,527
Balance (in shares) at Dec. 31, 2020	22,167,791
Balance at Dec. 31, 2020	$ 60	452,525	(356,501)	271	96,355
Exercise of options into ordinary shares (in shares)	237,054
Exercise of options into ordinary shares	$ 1	60			61
Share-based compensation		17,756			17,756
Other comprehensive income (loss)				(267)	(267)
Net loss			(82,368)		(82,368)
Balance (in shares) at Sep. 30, 2021	22,404,845
Balance at Sep. 30, 2021	$ 61	470,341	(438,869)	4	31,537
Balance (in shares) at Jun. 30, 2021	22,354,533
Balance at Jun. 30, 2021	$ 61	464,823	(408,658)	45	56,271
Exercise of options into ordinary shares (in shares)	50,312
Exercise of options into ordinary shares	$ 0	3			3
Share-based compensation		5,515			5,515
Other comprehensive income (loss)				(41)	(41)
Net loss			(30,211)		(30,211)
Balance (in shares) at Sep. 30, 2021	22,404,845
Balance at Sep. 30, 2021	$ 61	$ 470,341	$ (438,869)	$ 4	$ 31,537

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows From Operating Activities
Net loss	$ (82,368)	$ (97,958)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	618	295
Accrued financing on prepaid forward obligation	8,583	0
Amortization on marketable securities	343	386
Share-based compensation	17,756	21,499
Amortization of right of use asset	704	1,134
Lease liability	(914)	(1,157)
Changes in operating assets and liabilities:
Inventory	(1,844)	(1,346)
Accounts receivable	(737)	(2,810)
Prepaid expense and other current assets	(2,749)	(3,261)
Other non-current assets	(1,573)	0
Accounts payable and accrued expense	1,032	(2,506)
Employee related accrued expense	(3,078)	1,080
Other current liabilities	(595)	0
Net cash used in operating activities	(64,822)	(84,644)
Cash Flows From Investing Activities
Purchases of marketable securities	(51,594)	(29,687)
Sales of marketable securities	2,463
Maturities of marketable securities	44,625	74,503
Purchases of property and equipment	(550)	(1,043)
Net cash (used in) provided by investing activities	(5,056)	43,773
Cash Flows From Financing Activities
Proceeds from prepaid forward arrangement	72,417	0
Proceeds from exercise of options into ordinary shares	61	651
Issuances of ordinary shares, net of issuance expense	0	15,853
Issuance cost related to at-the-market issuances	(127)	(55)
Net cash provided by financing activities	72,351	16,449
Increase (Decrease) in Cash and Cash Equivalents	2,473	(24,422)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	54,090	50,211
Cash, Cash Equivalents and Restricted Cash at End of Period	56,563	25,789
Supplemental Disclosures of Non-Cash Activities
Non-cash new lease liabilities	(36)	51
Non-cash issuance cost	7	0
Exercise of options	$ 0	$ 40

Note 1 - Business and Nature of

Note 1 - Business and Nature of Operations	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1 Business and Nature of Operations Nature of Operations UroGen Pharma Ltd. is an Israeli company incorporated in April 2004 ( UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in October 2015 February 2016 ( UPL and UPI (together the “Company”) is a biopharmaceutical company focused on building and commercializing novel solutions that treat specialty cancers and urologic diseases. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s first Jelmyto 101 On April 15, 2020, Jelmyto first Jelmyto RTGel

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10 10 X. not not not 10 December 31, 2020, March 18, 2021. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. Intercompany balances and transactions have been eliminated during consolidation. The Company has experienced net losses since its inception and has an accumulated deficit o f $ September 30, 2021 December 31, 2020, The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 no not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results may Functional Currency The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar. Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as “Interest and other income, net.” Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three Cash and cash equivalents and marketable securities totaled $110.3 million as of September 30, 2021 320, Short-term investments are valued using models or other valuation methodologies that use Level 2 For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company’s product sales are recognized through the Company's arrangement with a single customer, a third not not Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not not The Company follows a two not 740 10 30 7 50% 15 Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first first . Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3 - 6.5 Furniture 5 - 16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 Prepaid Forward Obligation The Company is party to a transaction with RTW Investments (the “RTW Transaction”) in which the Company received funds to support the continued launch of Jelmyto 102 Jelmyto 102, 835 30, 9 Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no The Company accounts for leases in accordance with ASC Topic 842, . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may Because most of the Company’s leases do not ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360 10, Revenue Product sales from Jelmyto 606 Jelmyto third 340b Research and Development Expense Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expense, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third Selling General and Administrative Expense Selling, general and administrative expense consists primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach. Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. Recently Issued Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are not

Note 4 - Other Financial Inform

Note 4 - Other Financial Information	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Other Financial Information [Text Block]	Note 4 Other Financial Information Accounts Payable and Accrued Expense Accounts payable and accrued expense consists of the following as of September 30, 2021 December 31, 2020 September 30, December 31, 2021 2020 Accounts payable $ 4,060 $ 3,271 Accrued sales reserves 847 382 Accrued clinical expense 2,504 1,359 Accrued research and development expense 1,406 1,356 Accrued selling, general and administrative expense 1,638 2,440 Accrued other expense 607 1,215 Total accounts payable and accrued expense $ 11,062 $ 10,023 Interest and Other Income (Expense), Net Interest and other income (expense) consisted of the following as of September 30, 2021 2020 Nine Months Ended September 30, 2021 2020 Interest income $ 345 $ 1,719 Other finance (expense), net (76 ) (192 ) Total interest and other income, net $ 269 $ 1,527

Note 5 - Inventories

Note 5 - Inventories	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 5 Inventories Inventories consist of the following as of September 30, 2021 December 31, 2020 September 30, December 31, 2021 2020 Raw materials (1) $ 4,106 $ 1,051 Finished goods 1,275 913 Total inventories $ 5,381 $ 1,964 ( 1 $1.6 million of raw materials at September 30, 2021

Note 6 - Fair Value Measurement

Note 6 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6 Fair Value Measurements The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The carrying amounts of the Company’s other current assets, accounts payable and accrued liabilities are generally considered to be representative of their fair value because of the short-term nature of these instruments. No Assets and liabilities measured at fair value on a recurring basis based on Level 1 2 September 30, 2021 Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable September 30, Identical Assets Inputs 2021 (Level 1) (Level 2) Marketable securities: US government $ 19,401 $ 19,401 $ — Corporate bonds 12,349 — 12,349 Commercial paper 15,989 — 15,989 Money market funds (1) 35,924 35,924 — Certificates of deposit 7,204 — 7,204 Total marketable securities $ 90,867 $ 55,325 $ 35,542 ( 1 Included within cash and cash equivalents on the condensed consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 2 December 31, 2020 Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861 ( 1 Included within cash and cash equivalents on the condensed consolidated balance sheets. The Company’s in money market funds are valued based on publicly available quoted market prices for identical securities as of September 30, 2021 December 31, 2020.

Note 7 - Marketable Securities

Note 7 - Marketable Securities	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Note 7 Marketable Securities The following table summarizes the Company’s marketable securities as of September 30, 2021 Amortized Unrealized Unrealized Cost Basis Gains Losses Fair Value Marketable securities: US government $ 19,399 $ 2 $ — $ 19,401 Corporate bonds 12,348 1 — 12,349 Commercial paper 15,988 1 — 15,989 Money market funds (1) 35,924 — — 35,924 Certificates of deposit 7,204 — — 7,204 Total marketable securities $ 90,863 $ 4 $ — $ 90,867 ( 1 Included within cash and cash equivalents on the condensed consolidated balance sheets The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of September 30, 2021 September 30, 2021 As of September 30, 2021 not not September 30, 2021 no The Company’s marketable securities as of September 30, 2021 February 2022. September 30, December 31, 2021 2020 Maturities within one year $ 86,797 $ 88,898 Maturities after one year through three years 4,070 1,893 Total marketable securities $ 90,867 $ 90,791

Note 8 - Property and Equipment

Note 8 - Property and Equipment	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 8 Property and Equipment Property and equipment, consists of the following as of September 30, 2021 December 31, 2020 September 30, December 31, 2021 2020 Laboratory equipment $ 355 $ 333 Computer equipment and software 2,024 1,676 Furniture 597 597 Leasehold improvements 617 609 Manufacturing equipment 398 226 3,991 3,441 Less: accumulated depreciation and amortization (2,013 ) (1,395 ) Property and equipment, net $ 1,978 $ 2,046 Depreciation and amortization expense was $0.2 million and $0.6 three nine September 30, 2021 three nine September 30, 2020

Note 9 - Prepaid Forward Obliga

Note 9 - Prepaid Forward Obligation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Prepaid Forward Obligation Disclosure [Text Block]	Note 9 Prepaid Forward Obligation In March 2021, $72.4 Jelmyto 102. Jelmyto $200 $200 $300 $300 Jelmyto not Jelmyto $200 may 9.5% Jelmyto In addition, subject to FDA approval of UGN- 102, 102 $200 $200 $300 $300 not 102 Jelmyto Jelmyto In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than $300 million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a first Jelmyto 102, In May 2021, 72.4 835 30, not 12 The following table shows the activity with respect to the carrying value of the prepaid forward liability, in thousands: Prepaid forward obligation at closing of RTW Transaction $ 75,000 Capitalized closing costs (2,583 ) Financing on prepaid forward obligation 9,948 Amounts paid and payable (2,438 ) Carrying value of prepaid forward obligation as of September 30, 2021 $ 79,927

Note 10 - Leases

Note 10 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 10 Leases Operating Leases The Company has the following office and laboratory facility leases: • In April 2016, November 2014 2019. March 2019, three August 2022. • In September 2017, October 2017 February 2021. • In April 2018, July 10, 2018 March 2024. September 30, 2021 November 2019, January 1, 2020 March 2024. November 2019. September 30, 2021 842 10 25 2 842 10 25 3. • In November 2019, November 29, 2019 September 30, 2021 In addition, the Company has other operating office equipment and vehicle leases. The Company’s operating leases may not 2021 2023, The components of lease cost for the three nine September 30, 2021 Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Operating lease cost $ 259 $ 424 $ 786 $ 1,282 Sublease income (56 ) (56 ) (168 ) (168 ) Variable lease cost 15 28 51 114 $ 218 $ 396 $ 669 $ 1,228 The amounts recognized as of September 30, 2021 December 31, 2020 September 30, December 31, 2021 2020 Right of use asset $ 1,418 $ 2,158 Long-term lease liabilities 616 1,497 Other current liabilities 1,133 1,202 As of September 30, 2021 Supplemental information related to leases for the nine September 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 2,734 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases (in years) 1.68 Weighted-average discount rate of operating leases 5.51 % Subleases As of September 30, 2021 Operating Leases Years ending December 31, Remainder of 2021 $ 59 2022 243 2023 251 2024 49 2025 and thereafter — $ 602 Sublease income is recognized net within operating expense. Sublease income for the three nine September 30, 2021 Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Sublease income from fixed lease payments $ 56 $ 56 $ 168 $ 168

Note 11 - Revenue from Product

Note 11 - Revenue from Product Sales	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 11 Revenue From Product Sales Net product sales consist of the following for the three nine September 30, 2021 Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Jelmyto $ 11,351 $ 3,461 $ 31,868 $ 3,833

Note 12 - License and Collabora

Note 12 - License and Collaboration Agreements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	Note 12 License and Collaboration Agreements Allergan/AbbVie Agreement In October 2016, RTGel not In October 2017, 2 RTGel August 2020, 2 not may not Agenus Agreement In November 2019, not AGEN1884 AGEN1884 4 1 1 AGEN1884 201 Pursuant to the license agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first may 180 may 60 first nine may MD Anderson Agreement In January 2021, three 302 September 30, 2021

Note 13 - Shareholders' Equity

Note 13 - Shareholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 13 Shareholders Equity The Company had 100.0 million ordinary shares authorized for issuance as of September 30, 2021 December 31, 2020. September 30, 2021 December 31, 2020, one not

Note 14 - Share-based Compensat

Note 14 - Share-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 14 Share-Based Compensation In October 2010, The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Section 102 102” 102. 102, not 3 Employees are typically granted stock options and/or restricted stock units ("RSUs"), upon commencement of employment. Also, eligible employees may not three not The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first two one first two one The expected volatility is based on a mix of the Company’s historical volatility, and the historical volatility of comparable companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted. The expected term is the length of time until the expected dates of exercising the options and is estimated for employees using the simplified method due to insufficient specific historical information of employees’ exercise behavior, and for non-employees, and directors using the contractual term. In March 2017, 2017 "2017 April 2017. 2017 The maximum number of ordinary shares that was initially authorized for issuance under the 2017 January 1, 2018, October 12, 2018, 2017 June 8, 2020 2017 June 7, 2021, 2017 In May 2019, 2019 5635 4 5635 3 5635 1, not As of September 30, 2021 , 3,587,774 ordinary shares are subject to outstanding awards under the Company's share-based compensation plans and 1,362,156 ordinary shares remain available for future awards. The following table illustrates the effect of share-based compensation on the condensed consolidated statements of operations (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Research and development expense $ 971 $ 1,519 $ 3,119 $ 5,032 Selling, general and administrative expense 4,544 5,244 14,637 16,467 $ 5,515 $ 6,763 $ 17,756 $ 21,499 The total unrecognized compensation cost of options and RSUs at September 30, 2021

Note 15 - Income Taxes

Note 15 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 15 Income Taxes UroGen Pharma Ltd. is taxed under Israeli tax laws. As of September 30, 2021 2020, 2019 2018, nine September 30, 2021 may The Company has a liability for uncertain tax positions of $2.7 million as of September 30, 2021 September 30, 2021 2020. The Company operates on a global basis and is subject to tax laws and regulations in the U.S. and Israel. The estimate of the Company’s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may not 12

Note 16 - Related Parties

Note 16 - Related Parties	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16 Related Parties There were no nine September 30, 2021 2020.

Note 17 - Commitments and Conti

Note 17 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 17 Commitments and Contingencies In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of September 30, 2021 December 31, 2020. not Grants from the Israeli Innovation Authority in Israel ( IIA ) The Company has received grants from the IIA for research and development funding. Up until 2007, 8.2. 2008, On January 12, 2020, January 2004 September 2016. first 2020 three Leases See Note 10

Note 18 - Subsequent Events

Note 18 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 18 Subsequent Events See Note 12

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results may
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Functional Currency The U.S. dollar (“Dollar”) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional currency of the Company is the Dollar. Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency re-measurements are recorded in the condensed consolidated statements of operations as “Interest and other income, net.”
Cash, Cash Equivalents and Marketable Securities Policy [Policy Text Block]	Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three Cash and cash equivalents and marketable securities totaled $110.3 million as of September 30, 2021 320, Short-term investments are valued using models or other valuation methodologies that use Level 2 For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company’s product sales are recognized through the Company's arrangement with a single customer, a third not not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not not The Company follows a two not 740 10 30 7 50% 15
Inventory, Policy [Policy Text Block]	Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first first .
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3 - 6.5 Furniture 5 - 16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8
Prepaid Forward Obligation Policy [Policy Text Block]	Prepaid Forward Obligation The Company is party to a transaction with RTW Investments (the “RTW Transaction”) in which the Company received funds to support the continued launch of Jelmyto 102 Jelmyto 102, 835 30, 9
Lessee, Leases [Policy Text Block]	Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no The Company accounts for leases in accordance with ASC Topic 842, . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may Because most of the Company’s leases do not ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360 10,
Revenue [Policy Text Block]	Revenue Product sales from Jelmyto 606 Jelmyto third 340b
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expense, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Selling General and Administrative Expense Selling, general and administrative expense consists primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third
Share-based Payment Arrangement, Director [Policy Text Block]	Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method and to value the awards based on the single-option award approach.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are not

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment, Useful Life [Table Text Block]	Useful Lives Computers and software 3 Laboratory equipment 3 - 6.5 Furniture 5 - 16.5 Manufacturing equipment 2

Note 4 - Other Financial Info_2

Note 4 - Other Financial Information (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, December 31, 2021 2020 Accounts payable $ 4,060 $ 3,271 Accrued sales reserves 847 382 Accrued clinical expense 2,504 1,359 Accrued research and development expense 1,406 1,356 Accrued selling, general and administrative expense 1,638 2,440 Accrued other expense 607 1,215 Total accounts payable and accrued expense $ 11,062 $ 10,023
Interest Income and Interest Expense Disclosure [Table Text Block]	Nine Months Ended September 30, 2021 2020 Interest income $ 345 $ 1,719 Other finance (expense), net (76 ) (192 ) Total interest and other income, net $ 269 $ 1,527

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2021 2020 Raw materials (1) $ 4,106 $ 1,051 Finished goods 1,275 913 Total inventories $ 5,381 $ 1,964

Note 6 - Fair Value Measureme_2

Note 6 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable September 30, Identical Assets Inputs 2021 (Level 1) (Level 2) Marketable securities: US government $ 19,401 $ 19,401 $ — Corporate bonds 12,349 — 12,349 Commercial paper 15,989 — 15,989 Money market funds (1) 35,924 35,924 — Certificates of deposit 7,204 — 7,204 Total marketable securities $ 90,867 $ 55,325 $ 35,542 Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861

Note 7 - Marketable Securities

Note 7 - Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Marketable Securities [Table Text Block]	Amortized Unrealized Unrealized Cost Basis Gains Losses Fair Value Marketable securities: US government $ 19,399 $ 2 $ — $ 19,401 Corporate bonds 12,348 1 — 12,349 Commercial paper 15,988 1 — 15,989 Money market funds (1) 35,924 — — 35,924 Certificates of deposit 7,204 — — 7,204 Total marketable securities $ 90,863 $ 4 $ — $ 90,867
Investments Classified by Contractual Maturity Date [Table Text Block]	September 30, December 31, 2021 2020 Maturities within one year $ 86,797 $ 88,898 Maturities after one year through three years 4,070 1,893 Total marketable securities $ 90,867 $ 90,791

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2021 2020 Laboratory equipment $ 355 $ 333 Computer equipment and software 2,024 1,676 Furniture 597 597 Leasehold improvements 617 609 Manufacturing equipment 398 226 3,991 3,441 Less: accumulated depreciation and amortization (2,013 ) (1,395 ) Property and equipment, net $ 1,978 $ 2,046

Note 9 - Prepaid Forward Obli_2

Note 9 - Prepaid Forward Obligation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Activity in the Carrying Value of the Prepaid Forward Liability [Table Text Block]	Prepaid forward obligation at closing of RTW Transaction $ 75,000 Capitalized closing costs (2,583 ) Financing on prepaid forward obligation 9,948 Amounts paid and payable (2,438 ) Carrying value of prepaid forward obligation as of September 30, 2021 $ 79,927

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Operating lease cost $ 259 $ 424 $ 786 $ 1,282 Sublease income (56 ) (56 ) (168 ) (168 ) Variable lease cost 15 28 51 114 $ 218 $ 396 $ 669 $ 1,228
Assets and Liabilities, Lessee [Table Text Block]	September 30, December 31, 2021 2020 Right of use asset $ 1,418 $ 2,158 Long-term lease liabilities 616 1,497 Other current liabilities 1,133 1,202
Schedule of Supplemental Information Related to Leases [Table Text Block]	Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 2,734 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases (in years) 1.68 Weighted-average discount rate of operating leases 5.51 %
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Operating Leases Years ending December 31, Remainder of 2021 $ 59 2022 243 2023 251 2024 49 2025 and thereafter — $ 602
Lessee, Operating Lease, Sublease Income Recognized Net in Operating Expenses [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Sublease income from fixed lease payments $ 56 $ 56 $ 168 $ 168

Note 11 - Revenue from Produc_2

Note 11 - Revenue from Product Sales (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Jelmyto $ 11,351 $ 3,461 $ 31,868 $ 3,833

Note 14 - Share-based Compens_2

Note 14 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Research and development expense $ 971 $ 1,519 $ 3,119 $ 5,032 Selling, general and administrative expense 4,544 5,244 14,637 16,467 $ 5,515 $ 6,763 $ 17,756 $ 21,499

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (438,869)	$ (356,501)

Note 3 - Significant Accounti_3

Note 3 - Significant Accounting Policies (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
Cash, Cash Equivalents, and Short-term Investments, Total	$ 110.3

Note 3 - Significant Accounti_4

Note 3 - Significant Accounting Policies - Useful Lives of Property and Equipment (Details)	9 Months Ended
	Sep. 30, 2021
Computers and Software [Member]
Useful life (Year)	3 years
Laboratory Equipment [Member] | Minimum [Member]
Useful life (Year)	3 years
Laboratory Equipment [Member] | Maximum [Member]
Useful life (Year)	6 years 6 months
Furniture [Member[ | Minimum [Member]
Useful life (Year)	5 years
Furniture [Member[ | Maximum [Member]
Useful life (Year)	16 years 6 months
Manufacturing Equipment [Member]
Useful life (Year)	2 years

Note 4 - Other Financial Info_3

Note 4 - Other Financial Information - Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts payable	$ 4,060	$ 3,271
Accrued sales reserves	847	382
Accrued clinical expense	2,504	1,359
Accrued research and development expense	1,406	1,356
Accrued selling, general and administrative expense	1,638	2,440
Accrued other expense	607	1,215
Total accounts payable and accrued expense	$ 11,062	$ 10,023

Note 4 - Other Financial Info_4

Note 4 - Other Financial Information - Interest and Other Income (Expense), Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Interest income			$ 345	$ 1,719
Other finance (expense), net			(76)	(192)
Total interest and other income, net	$ 57	$ 308	$ 269	$ 1,527

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Thousands		Sep. 30, 2021	Dec. 31, 2020
Inventory, Raw Materials, Net of Reserves	[1]	$ 4,106	$ 1,051
Other Noncurrent Assets [Member]
Inventory, Raw Materials, Net of Reserves		$ 1,600
[1]	$1.0 million of raw materials at September 30, 2021 are included within other non-current assets on the condensed consolidated balance sheets.

Note 5 - Inventories - Inventor

Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands		Sep. 30, 2021	Dec. 31, 2020
Raw materials(1)	[1]	$ 4,106	$ 1,051
Finished goods		1,275	913
Total inventories		$ 5,381	$ 1,964
[1]	$1.0 million of raw materials at September 30, 2021 are included within other non-current assets on the condensed consolidated balance sheets.

Note 6 - Fair Value Measureme_3

Note 6 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2021	Dec. 31, 2020
Fair value		$ 90,867	$ 90,791
US Treasury and Government [Member]
Fair value		19,401
Corporate Debt Securities [Member]
Fair value		12,349
Money Market Funds [Member]
Fair value	[1]	35,924
Commercial Paper [Member]
Fair value		15,989
Certificates of Deposit [Member]
Fair value		7,204
Fair Value, Recurring [Member]
Fair value		90,867	90,791
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value		55,325	68,930
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value		35,542	21,861
Fair Value, Recurring [Member] | US Treasury and Government [Member]
Fair value		19,401	29,186
Fair Value, Recurring [Member] | US Treasury and Government [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value		19,401	29,186
Fair Value, Recurring [Member] | US Treasury and Government [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value		0	0
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair value		12,349	21,861
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value		0	0
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value		12,349	21,861
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair value	[2]	35,924	39,744
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value	[2]	35,924	39,744
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value	[2]	0	$ 0
Fair Value, Recurring [Member] | Commercial Paper [Member]
Fair value		15,989
Fair Value, Recurring [Member] | Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value		0
Fair Value, Recurring [Member] | Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value		15,989
Fair Value, Recurring [Member] | Certificates of Deposit [Member]
Fair value		7,204
Fair Value, Recurring [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Fair value		0
Fair Value, Recurring [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Fair value		$ 7,204
[1]	Included within cash and cash equivalents on the condensed consolidated balance sheets
[2]	Included within cash and cash equivalents on the condensed consolidated balance sheets.

Note 7 - Marketable Securitie_2

Note 7 - Marketable Securities (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total	$ 0.1
Debt Securities, Available-for-sale, Unrealized Loss Position, Total	$ 11.9
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions	13

Note 7 - Marketable Securitie_3

Note 7 - Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands		Sep. 30, 2021	Dec. 31, 2020
Amortized cost basis		$ 90,863
Unrealized gains		4
Unrealized losses		0
Fair value		90,867	$ 90,791
US Treasury and Government [Member]
Amortized cost basis		19,399
Unrealized gains		2
Unrealized losses		0
Fair value		19,401
Corporate Debt Securities [Member]
Amortized cost basis		12,348
Unrealized gains		1
Unrealized losses		0
Fair value		12,349
Commercial Paper [Member]
Amortized cost basis		15,988
Unrealized gains		1
Unrealized losses		0
Fair value		15,989
Money Market Funds [Member]
Amortized cost basis	[1]	35,924
Unrealized gains	[1]	0
Unrealized losses	[1]	0
Fair value	[1]	35,924
Certificates of Deposit [Member]
Amortized cost basis		7,204
Unrealized gains		0
Unrealized losses		0
Fair value		$ 7,204
[1]	Included within cash and cash equivalents on the condensed consolidated balance sheets

Note 7 - Marketable Securitie_4

Note 7 - Marketable Securities - Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Maturities within one year	$ 86,797	$ 88,898
Maturities after one year through three years	4,070	1,893
Total marketable securities	$ 90,867	$ 90,791

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Depletion and Amortization, Total	$ 200	$ 100	$ 618	$ 295

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 3,991	$ 3,441
Less: accumulated depreciation and amortization	(2,013)	(1,395)
Property and equipment, net	1,978	2,046
Laboratory Equipment [Member]
Property and equipment, gross	355	333
Computers and Software [Member]
Property and equipment, gross	2,024	1,676
Furniture [Member[
Property and equipment, gross	597	597
Leasehold Improvements [Member]
Property and equipment, gross	617	609
Manufacturing Equipment [Member]
Property and equipment, gross	$ 398	$ 226

Note 9 - Prepaid Forward Obli_3

Note 9 - Prepaid Forward Obligation (Details Textual) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	May 31, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Prepaid Forward Arrangement, Net			$ 72,417	$ 0
RTW Investments [Member]
Proceeds from Prepaid Forward Obligation	$ 75,000	$ 75,000
Proceeds from Prepaid Forward Arrangement, Net	$ 72,400	72,400
Prepaid Forward Agreement, Minimum Future Cash Flows		$ 300,000
Prepaid Forward Obligation, Expected Cash Flows in Next Twelve Months			$ 0
RTW Investments [Member] | Sales of Up to $200 Million [Member] | Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		9.50%
Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales		3.50%
RTW Investments [Member] | Sales Between $200 Million and $300 Million [Member] | Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		3.00%
RTW Investments [Member] | Sales Over $300 Million [Member] | Jelmyto [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		1.00%
RTW Investments [Member] | Sales Up to $200 Million with FDA Approval [Member] | UGN-102 [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		2.50%
RTW Investments [Member] | Sales Between $200 Million and $300 Million with FDA Approval [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		1.00%
RTW Investments [Member] | Sales Over $300 Million with FDA Approval [Member]
Prepaid Forward Agreement, Future Cash Payments, Percentage of Net Sales		0.50%
Prepaid Forward Agreement, Future Cash Flows, Increase in Percentage of Net Sales		1.50%

Note 9 - Prepaid Forward Obli_4

Note 9 - Prepaid Forward Obligation - Activity in the Carrying Value of the Prepaid Forward Liability (Details) - USD ($) $ in Thousands	3 Months Ended		5 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Prepaid forward obligation at closing of RTW Transaction			$ 75,000	$ 0
Capitalized closing costs			(2,583)
Financing on prepaid forward obligation	$ 6,828	$ 0	9,948	9,948	$ 0
Amounts paid and payable			(2,438)
Carrying value of prepaid forward obligation as of September 30, 2021	$ 79,927		$ 79,927	$ 79,927

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Nov. 29, 2019	Jul. 10, 2018
Lessor, Operating Lease, Payments to be Received, Total	$ 602
Operating Lease, Impairment Loss	0
Lease Agreement for Office in Los Angeles, California [Member] | UroGen Pharma Inc. [Member]
Incentive from Lessor			$ 200
Operating Lease, Liability, Total	700
Lessor, Operating Lease, Payments to be Received, Total	500
Lease Agreement for Office in Princeton, New Jersey [Member] | UroGen Pharma Inc. [Member]
Operating Lease, Liability, Total	$ 700
Lessee, Operating Lease, Term of Contract (Month)		38 months

Note 10 - Leases - Components o

Note 10 - Leases - Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating lease cost	$ 259	$ 424	$ 786	$ 1,282
Sublease income	(56)	(56)	(168)	(168)
Variable lease cost	15	28	51	114
Lease, Cost, Total	$ 218	$ 396	$ 669	$ 1,228

Note 10 - Leases - Amounts of A

Note 10 - Leases - Amounts of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Right of use asset	$ 1,418	$ 2,158
Long-term lease liabilities	616	1,497
Other current liabilities	$ 1,133	$ 1,202

Note 10 - Leases - Supplemental

Note 10 - Leases - Supplemental Information Related to Leases (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Operating cash flows from operating leases	$ 2,734
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 135
Weighted-average remaining lease term of operating leases (Year)	1 year 8 months 4 days
Weighted-average discount rate of operating leases	5.51%

Note 10 - Leases - Undiscounted

Note 10 - Leases - Undiscounted Cash Flows to be Received Under Sublease (Details) $ in Thousands	Sep. 30, 2021USD ($)
Remainder of 2021	$ 59
2022	243
2023	251
2024	49
2025 and thereafter	0
Lessor, Operating Lease, Payments to be Received, Total	$ 602

Note 10 - Leases - Sublease Inc

Note 10 - Leases - Sublease Income Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sublease income from fixed lease payments	$ 56	$ 56	$ 168	$ 168

Note 11 - Revenue from Produc_3

Note 11 - Revenue from Product Sales - Net Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 11,351	$ 3,461	$ 31,868	$ 3,833
Jelmyto [Member]
Revenue	$ 11,351	$ 3,461	$ 31,868	$ 3,833

Note 12 - License and Collabo_2

Note 12 - License and Collaboration Agreements (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
	Jan. 31, 2021	Nov. 30, 2019	Sep. 30, 2021
Agenus Inc. [Member]
Payments for License Agreement		$ 10,000,000
License Agreement, Maximum Payable for Certain Clinical Development and Regulatory Milestones		115,000,000
License Agreement, Maximum Payable for Certain Commercial Milestones		$ 85,000,000
License Agreement, Expiration Term (Year)		15 years
Agenus Inc. [Member] | Minimum [Member]
License Agreement, Royalty, Percentage of Net Sales of Licensed Products		14.00%
Agenus Inc. [Member] | Maximum [Member]
License Agreement, Royalty, Percentage of Net Sales of Licensed Products		20.00%
MD Anderson [Member]
Collaboration Agreement, Term (Year)	3 years
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross			$ 500,000

Note 13 - Shareholders' Equity

Note 13 - Shareholders' Equity (Details Textual) - shares	Sep. 30, 2021	Dec. 31, 2020
Common Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Common Stock, Shares, Issued, Total (in shares)	22,404,845	22,167,791

Note 14 - Share-based Compens_3

Note 14 - Share-based Compensation (Details Textual) - USD ($) $ in Millions	Jun. 07, 2021	Jun. 08, 2020	Oct. 12, 2018	Jan. 01, 2018	Sep. 30, 2021	Mar. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					3,587,774
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					1,362,156
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 22.9
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 9 months 3 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					2 years
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					2 years
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.00%
Share Option Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					3 years
Share-based Compensation Arrangement By Share-based Payment Award, Individual Voting Powers, Percentage					10.00%
Two Thousand Seventeen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,350,167	3,950,167	3,550,167	1,650,167		1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	400,000	400,000	1,900,000	250,167
The 2019 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					900,000
Maximum [Member] | Share Option Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)					10 years
Minimum [Member] | Share Option Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					100.00%
Share-based Compensation Arrangement By Share-based Payment Award, Percentage of Purchase Price for Individuals Having More than Ten Percent of Combined Voting Power					110.00%

Note 14 - Share-based Compens_4

Note 14 - Share-based Compensation - Effect of Share-based Compensation On the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based compensation	$ 5,515	$ 6,763	$ 17,756	$ 21,499
Research and Development Expense [Member]
Share-based compensation	971	1,519	3,119	5,032
Selling, General and Administrative Expenses [Member]
Share-based compensation	$ 4,544	$ 5,244	$ 14,637	$ 16,467

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
Unrecognized Tax Benefits, Ending Balance	$ 2.7
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	$ 0.7

Note 17 - Commitments and Con_2

Note 17 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Mar. 31, 2020
Accrued Royalties		$ 6.6
Maximum Percentage of Commitment to Continue Employment of Research and Development Jobs	75.00%
Maximum Term for Commitment to Continue Employment of Research and Development Jobs (Year)	3 years